Business article - June 2, 2015
Orphan Drugs Spur M&A Interest
Thanks to the potential for higher prices, limited competition and favorable regulations, orphan drugs continue to be popular to manufacture and also attractive to buy, and Moody’s predicts they will continue to generate merger and acquistion activity. Nearly half of recent acquisitons involved orphan drugs, or medications that treat serious conditions that affect fewer than […]
Economic Analysis - February 8, 2015
European M&A Lagged in 2014
Mergers and acquisitions (M&A) activity lagged in the European biopharmaceutical market in 2014, analysts said. Healthcare investor HBM Partners presented the figures in its annual biotech M&A report. The $500 million European, VC-backed biotechs generated in upfront fees represents a 50 percent drop on 2013 and a 27 percent decrease compared with the mean of the […]
